WO2023002431 - AUTOMATED SYNTHESIS OF POLYMERIC DRUGS
National phase entry:
Publication Number
WO/2023/002431
Publication Date
26.01.2023
International Application No.
PCT/IB2022/056757
International Filing Date
21.07.2022
Title **
[English]
AUTOMATED SYNTHESIS OF POLYMERIC DRUGS
[French]
SYNTHÈSE AUTOMATISÉE DE MÉDICAMENTS POLYMÈRES
Applicants **
SONY GROUP CORPORATION
Inventors
MATRAY, Tracy
VANBRUNT, Michael
MCCUTCHEON, John Michael
Priority Data
63/224,777
22.07.2021
US
63/250,892
30.09.2021
US
63/252,993
06.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7160 | |
| EPO | Filing, Examination, Granting | 154974 | |
| Japan | Filing, Examination, Granting | 5251 | |
| South Korea | Filing, Examination, Granting | 11166 | |
| USA | Filing, Examination, Granting | 34290 |
Total:
212,841
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
, M, p, q, m, and n are as defined herein. Additional compounds, methods of preparation, pharmaceutical compositions, and methods of treatment related to compounds of Structure (I) are also provided.[French]
, M, p, q, m, et n sont tels que définis dans la description. L'invention concerne également des composés supplémentaires, des procédés de préparation, des compositions pharmaceutiques et des procédés de traitement associés à des composés de structure (I).